Cost-effectiveness of first-line immune checkpoint inhibitor therapies, alone or combined with targeted agents, for unresectable hepatocellular carcinoma in China: an economic evaluation using network meta-analysis

Read full text Summarise with VIRAT
Authors: Wei Li, Li Wan, Sijie He
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This economic evaluation aimed to identify a cost-effective first-line treatment for unresectable hepatocellular carcinoma (uHCC) within China’s healthcare system, specifically focusing on immune checkpoint inhibitor (ICI)-based regimens relevant to clinical practice, including newly approved options. Relative efficacy was synthesized from six phase III trials forming a star-shaped network with sorafenib as the common comparator, using a Bayesian network meta-analysis with Royston-Parmar models, accounting for non-proportional hazards. A 10-year, three-state partitioned survival model estimated discounted (5% annually) costs and quality-adjusted life-years (QALYs). Sensitivity analyses tested structural and parameter uncertainty. After discounting, camrelizumab-rivoceranib provided more QALYs at a lower cost than three other ICI-based combinations (anlotinib-penpulimab, sintilimab-bevacizumab biosimilar, and toripalimab-bevacizumab), establishing strict dominance. The incremental cost per QALY gained was $10,715 for tislelizumab versus sorafenib, $56,796 for camrelizumab-rivoceranib versus tislelizumab, and $294,795 for atezolizumab-bevacizumab versus camrelizumab-rivoceranib. All findings remained robust in sensitivity analyses. For uHCC in China, tislelizumab represents a cost-effective choice at the current willingness-to-pay threshold of $40,344 per QALY (3×gross domestic product (GDP) per capita). This analysis provides timely evidence to inform clinical practice and policy decisions regarding the allocation of finite healthcare resources.

Fields of Study & Subjects

Health Systems Economic Evaluations Quality of Life Hepatocellular Carcinoma Treatment and Prognosis Economic and Financial Impacts of Cancer

Publication details

Journal / source
Figshare
Publication date
20 March 2026
Language
EN